Eiji Sugiyama

Eiji Sugiyama

Auto-generated profile, based on publicly available information

Eiji Sugiyama

School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KKKeisuke Kitakaze
Keisuke Kitakaze
YMYasumichi Mizutani
Yasumichi Mizutani
ESEiji Sugiyama
Eiji Sugiyama
CTChikako Tasaki
Chikako Tasaki
DTDaisuke Tsuji
Daisuke Tsuji
KIKouji Itou
Kouji Itou
GM2 gangliosidoses, including Tay-Sachs and Sandhoff diseases, are neurodegenerative lysosomal storage diseases that are caused by deficiency of β-hexosaminidase A, which comprises an αβ heterodimer. There are no effective treatments for these diseases; however, various strategies aimed at restoring β-hexosaminidase A have been explored. Here, we produced a modified human hexosaminidase subunit β (HexB), which we have termed mod2B, composed of homodimeric β subunits that contain amino acid sequences from the α subunit that confer GM2 ganglioside–degrading activity and protease resistance. We also developed fluorescent probes that allow visualization of endocytosis of mod2B via mannose 6-phosphate receptors and delivery of mod2B to lysosomes in GM2 gangliosidosis models. In addition, we applied imaging mass spectrometry to monitor efficacy of this approach in Sandhoff disease model mice. Following i.c.v. administration, mod2B was widely distributed and reduced accumulation of GM2, asialo-GM2, and bis(monoacylglycero)phosphate in brain regions including the hypothalamus, hippocampus, and cerebellum. Moreover, mod2B administration markedly improved motor dysfunction and a prolonged lifespan in Sandhoff disease mice. Together, the results of our study indicate that mod2B has potential for intracerebrospinal fluid enzyme replacement therapy and should be further explored as a gene therapy for GM2 gangliosidoses.

12 February 2021 in The Analyst
Verified
Journal Article
Closed access
PDF file
DADaiki Asakawa
Daiki Asakawa
HMHajime Mizuno
Hajime Mizuno
ESEiji Sugiyama
Eiji Sugiyama
Kenichiro TodorokiKenichiro Todoroki
Kenichiro Todoroki
Liquid chromatography–tandem mass spectrometry (LC–MS/MS) is interfaced with electrospray ionization (ESI), which generally produces intact gas-phase ions of biomolecules. However, ESI induces the fragmentation of tryptophan-derived metabolites, which are known to act as neurotransmitters and psychoactive drugs. Tryptophan-derived metabolites undergo N–Cα bond dissociation during ESI, producing a fragment ion with a spiro[cyclopropane-indolium] backbone. Fragmentation is suppressed by the presence of an α-carboxyl group and the modification of amino groups. In particular, tryptamine and serotonin, which lack such functional groups, produce more intense fragment-ion signals than protonated molecules. The multiple reaction monitoring (MRM)-based quantitative analysis of tryptamine and serotonin used the fragment ions produced from in-source collision-induced dissociation as the precursor ions, which improved the signal-to-noise ratio of the resulting spectra. The present method allows for the quantitative analysis of tryptamine and serotonin with high sensitivity.



10 February 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MSMasayoshi Saito
Masayoshi Saito
SHSatoshi Horie
Satoshi Horie
HYHidenori Yasuhara
Hidenori Yasuhara
AKAkane Kashimura
Akane Kashimura
ESEiji Sugiyama
Eiji Sugiyama
Kenichiro TodorokiKenichiro Todoroki
Kenichiro Todoroki

1 January 1993 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
TIT. Inoue
T. Inoue
KKK. Kushida
K. Kushida
GKG. Kobayashi
G. Kobayashi
AMA. Machida
A. Machida
KYK. Yamazaki
K. Yamazaki
HWHiroko Watanabe
Hiroko Watanabe